Endothelin receptor antagonists: actions and rationale for their development.
Warner
T D
TD
William Harvey Research Institute, Medical College of St. Bartholomew's Hospital, London, U.K.
Battistini
B
B
Doherty
A M
AM
Corder
R
R
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D016282:Aspartic Acid Endopeptidases / Q000037:antagonists & inhibitors; D004195:Disease Models, Animal; D015195:Drug Design; D065128:Endothelin Receptor Antagonists; D000072396:Endothelin-Converting Enzymes; D016232:Endothelins / Q000037:antagonists & inhibitors* / Q000096:biosynthesis / Q000502:physiology; D006801:Humans; D008666:Metalloendopeptidases; D009842:Oligopeptides / Q000627:therapeutic use; D010456:Peptides, Cyclic / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use; D017466:Receptors, Endothelin / Q000187:drug effects / Q000235:genetics; D013449:Sulfonamides / Q000627:therapeutic use; D000096926:Benzenesulfonamides
D000911:Antibodies, Monoclonal; D016282:Aspartic Acid Endopeptidases; D065128:Endothelin Receptor Antagonists; D000072396:Endothelin-Converting Enzymes; D016232:Endothelins; D008666:Metalloendopeptidases; D009842:Oligopeptides; D010456:Peptides, Cyclic; D011743:Pyrimidines; D017466:Receptors, Endothelin; D013449:Sulfonamides; C076213:PD 142893; C083751:Ro 46-2005; D000096926:Benzenesulfonamides; C072247:cyclo(Trp-Asp-Pro-Val-Leu)